256 related articles for article (PubMed ID: 29363543)
1. Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERα
Shea MP; O'Leary KA; Fakhraldeen SA; Goffin V; Friedl A; Wisinski KB; Alexander CM; Schuler LA
Cancer Res; 2018 Apr; 78(7):1672-1684. PubMed ID: 29363543
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
3. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
4. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
[TBL] [Abstract][Full Text] [Related]
5. Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo.
O'Leary KA; Jallow F; Rugowski DE; Sullivan R; Sinkevicius KW; Greene GL; Schuler LA
Endocrinology; 2013 Dec; 154(12):4483-92. PubMed ID: 24064365
[TBL] [Abstract][Full Text] [Related]
6. Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
Fowler AM; Chan SR; Sharp TL; Fettig NM; Zhou D; Dence CS; Carlson KE; Jeyakumar M; Katzenellenbogen JA; Schreiber RD; Welch MJ
J Nucl Med; 2012 Jul; 53(7):1119-26. PubMed ID: 22669982
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death.
Cook KL; Clarke PA; Parmar J; Hu R; Schwartz-Roberts JL; Abu-Asab M; Wärri A; Baumann WT; Clarke R
FASEB J; 2014 Sep; 28(9):3891-905. PubMed ID: 24858277
[TBL] [Abstract][Full Text] [Related]
8. High collagen density augments mTOR-dependent cancer stem cells in ERα+ mammary carcinomas, and increases mTOR-independent lung metastases.
Shea MP; O'Leary KA; Wegner KA; Vezina CM; Schuler LA
Cancer Lett; 2018 Oct; 433():1-9. PubMed ID: 29935374
[TBL] [Abstract][Full Text] [Related]
9. Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.
Barcus CE; O'Leary KA; Brockman JL; Rugowski DE; Liu Y; Garcia N; Yu M; Keely PJ; Eliceiri KW; Schuler LA
Breast Cancer Res; 2017 Jan; 19(1):9. PubMed ID: 28103936
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells.
Vazquez-Martin A; Cufí S; López-Bonet E; Corominas-Faja B; Cuyàs E; Vellon L; Iglesias JM; Leis O; Martín AG; Menendez JA
Cell Cycle; 2013 Nov; 12(22):3471-7. PubMed ID: 24107627
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T
BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer.
Fanning SW; Greene GL
Endocrinology; 2019 Apr; 160(4):759-769. PubMed ID: 30753408
[TBL] [Abstract][Full Text] [Related]
13. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
[TBL] [Abstract][Full Text] [Related]
14. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
[TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
16. Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical study.
Wang G; Chen C; Pai P; Korangath P; Sun S; Merino VF; Yuan J; Li S; Nie G; Stearns V; Sukumar S
Carcinogenesis; 2019 Jul; 40(7):903-913. PubMed ID: 31046118
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα
Puyang X; Furman C; Zheng GZ; Wu ZJ; Banka D; Aithal K; Agoulnik S; Bolduc DM; Buonamici S; Caleb B; Das S; Eckley S; Fekkes P; Hao MH; Hart A; Houtman R; Irwin S; Joshi JJ; Karr C; Kim A; Kumar N; Kumar P; Kuznetsov G; Lai WG; Larsen N; Mackenzie C; Martin LA; Melchers D; Moriarty A; Nguyen TV; Norris J; O'Shea M; Pancholi S; Prajapati S; Rajagopalan S; Reynolds DJ; Rimkunas V; Rioux N; Ribas R; Siu A; Sivakumar S; Subramanian V; Thomas M; Vaillancourt FH; Wang J; Wardell S; Wick MJ; Yao S; Yu L; Warmuth M; Smith PG; Zhu P; Korpal M
Cancer Discov; 2018 Sep; 8(9):1176-1193. PubMed ID: 29991605
[TBL] [Abstract][Full Text] [Related]
18. Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.
Song W; He D; Chen Y; Yeh CR; Hsu I; Huang Q; Zhang X; Chang LS; Zuo L; Chen J; Doersch KM; Chang C; Li L; Yeh S
Mol Oncol; 2018 Dec; 12(12):2055-2071. PubMed ID: 30171816
[TBL] [Abstract][Full Text] [Related]
19. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.
Pandian V; Ramraj S; Khan FH; Azim T; Aravindan N
Stem Cell Res Ther; 2015 Feb; 6(1):2. PubMed ID: 25888913
[TBL] [Abstract][Full Text] [Related]
20. Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid.
Berardi DE; Flumian C; Campodónico PB; Urtreger AJ; Diaz Bessone MI; Motter AN; Bal de Kier Joffé ED; Farias EF; Todaro LB
Cell Oncol (Dordr); 2015 Aug; 38(4):289-305. PubMed ID: 26044847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
